Citigroup Inc. Boosts Stock Holdings in Phibro Animal Health Corporation $PAHC

Citigroup Inc. lifted its position in Phibro Animal Health Corporation (NASDAQ:PAHC) by 112.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,941 shares of the company’s stock after acquiring an additional 29,066 shares during the quarter. Citigroup Inc. owned approximately 0.14% of Phibro Animal Health worth $2,223,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capricorn Fund Managers Ltd bought a new position in shares of Phibro Animal Health during the third quarter valued at about $10,233,000. JPMorgan Chase & Co. grew its position in Phibro Animal Health by 1,730.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after purchasing an additional 225,110 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Phibro Animal Health in the 3rd quarter valued at about $8,931,000. Ranger Investment Management L.P. increased its stake in Phibro Animal Health by 101.1% in the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock valued at $9,143,000 after buying an additional 179,975 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 110,842 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96. Following the completion of the transaction, the chief executive officer directly owned 122,958 shares of the company’s stock, valued at approximately $5,948,708.04. This represents a 47.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 299,200 shares of company stock valued at $14,249,723 in the last quarter. 50.13% of the stock is currently owned by corporate insiders.

Phibro Animal Health Stock Performance

NASDAQ PAHC opened at $47.92 on Friday. The company has a market capitalization of $1.94 billion, a PE ratio of 21.30, a price-to-earnings-growth ratio of 0.74 and a beta of 0.74. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $56.30. The company has a 50-day simple moving average of $45.11 and a 200 day simple moving average of $41.63.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $373.91 million for the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, research analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, March 4th. Phibro Animal Health’s payout ratio is 21.33%.

Wall Street Analyst Weigh In

PAHC has been the topic of a number of research analyst reports. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research report on Friday, February 6th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $37.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.